“Mounjaro® KwikPen™ 2.5 mg is the initial starter dose of tirzepatide, designed to help patients begin therapy safely and comfortably. It is primarily used during the dose-initiation phase to allow the body to gradually adjust to the medication while minimizing gastrointestinal side effects.

Tirzepatide is a novel dual-acting incretin mimetic that activates both Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptors. This dual mechanism improves blood glucose control by increasing insulin secretion in a glucose-dependent manner, suppressing excess glucagon release, slowing gastric emptying, and reducing appetite.

The 2.5 mg strength is not intended for long-term glycemic control, but rather as a tolerability dose administered once weekly for the first four weeks. It helps reduce nausea, vomiting, and digestive discomfort often associated with incretin-based therapies.

Each pre-filled KwikPen contains four fixed doses, sufficient for one month of treatment. The pen is user-friendly, discreet, and designed for simple subcutaneous administration in the abdomen, thigh, or upper arm.”